BTCY
Biotricity Inc

826
Mkt Cap
$13.14M
Volume
305,804.00
52W High
$0.8334
52W Low
$0.23
PE Ratio
-2.49
BTCY Fundamentals
Price
$0.3999
Prev Close
$0.47
Open
$0.46
50D MA
$0.5419
Beta
3.12
Avg. Volume
22,270.21
EPS (Annual)
-$0.5548
P/B
-0.38
Rev/Employee
$299,789.00
Loading...
Loading...
News
all
press releases
Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates
Biotricity (BTCY) delivered earnings and revenue surprises of +62.50% and -0.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·27d ago
News Placeholder
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +15.00% and +4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +158.33% and +3.47%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) delivered earnings and revenue surprises of +18.42% and +6.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
iRhythm Technologies (IRTC) Reports Q3 Loss, Beats Revenue Estimates
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of +83.33% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Biotricity (BTCY) This Year?
Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Zacks·4mo ago
News Placeholder
Biotricity (BTCY) Upgraded to Buy: Here's Why
Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4mo ago
News Placeholder
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
Here is how Cardinal Health (CAH) and Biotricity Inc. (BTCY) have performed compared to their sector so far this year.
Zacks·5mo ago
News Placeholder
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
REDWOOD CITY, CA / ACCESSWIRE / April 2, 2024 / Biotricity Inc. (NASDAQ:BTCY) ('Biotricity' or the 'Company'), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic...
Accesswire·2y ago

Latest BTCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.